Prothena Corporation plc (0Y3M.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 05:03PM BST. Market open.
| Previous close | 20.29 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 345 |
| Market cap | 7.175M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | 1.34 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireProthena to Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024--Prothena announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
ZacksEarnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
© 2024 Yahoo. All rights reserved.